Acoustic Neuroma Market Research Report-  Global  Forecast till 2027

Acoustic Neuroma Market Research Report- By Type (Unilateral, Bilateral) By Diagnosis (Audiometry, Electronystagmography, MRI) By Treatment (Monitoring, Surgery, Radiaotherapy, Supportive Therapy) By Drug Class, By End User– Global Forecast till 2027

ID: MRFR/MED/3671-HCR | | Region: Global | 85 pages

Market Scenario


An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.


Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.


Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the global acoustic neuroma market.


Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore,  these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).


The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.


The global market of acoustic neuroma is expected to grow at a CAGR of approximately 7.6% during the forecast period 2017-2023.


Intended Audience



  • Acoustic Neuroma Drug Suppliers

  • Acoustic Neuroma Drug Manufacturers

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.


On the basis of type, the market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.


On the basis of diagnosis, the market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.


On the basis of drug class, the market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.


On the basis of treatment, the market is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is subsegmented radiosurgery, craniotomy, and microsurgery removal


On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.


Regional Analysis


The global acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.


North America is projected to hold the largest share of the global acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).


The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.


Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.


Key Players


Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.


Some of key the players in the global acoustic neuroma market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others


Research Methodology
Acoustic Neuroma Market


Sources: Annual reports, Press release, White paper, and Company presentation


 



Frequently Asked Questions (FAQ) :


acoustic neuroma market is expected to expand exponentially at 7.6% CAGR from 2017 to 2023.

acoustic neuroma market is driven by the increasing cases of acoustic neurom

Diagnosis of acoustic neuroma by gadolinium enhanced magnetic resonance imaging (MRI) is expected to be beneficial to the global acoustic neuroma market in the coming years.

The probability of severe headaches after surgery can impede by the global acoustic neuroma market growth.

North America can dominate the global acoustic neuroma market till 2025.

Pfizer Inc., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ag, Toshiba Medical Systems Corporation, GE Healthcare, Philips Healthcare, Shimadzu Corporation, and Siemens Healthcare are notable players currently working in the global acoustic neuroma market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Acoustic Neuroma Market, By Type

6.1 Introduction

6.2 Unilateral Vestibular Schwannomas

6.2.1 Market Estimates & Forecast, 2020 – 2023

6.3 Bilateral Vestibular Schwannomas

6.3.1 Market Estimates & Forecast, 2020 – 2023

Chapter 7. Global Acoustic Neuroma Market, By Diagnosis

7.1 Introduction

7.2 Hearing Test (Audiometry),

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Electronystagmography

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Magnetic Resonance Imaging (MRI)

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Others

Chapter 8. Global Acoustic Neuroma Market, By Drug Class

8.1 Introduction

8.2 Anticonvulsants

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Corticosteroids

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Osmotic Diuretics

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Pain Killers

8.5.1 Market Estimates & Forecast, 2020 – 2027

8.6 Others

Chapter 9. Global Acoustic Neuroma Market, By Treatment

9.1 Introduction

9.2 Monitoring

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.3 Surgery

9.3.1 Market Estimates & Forecast, 2020 – 2027

9.3.2 Radiosurgery

9.3.2.1 Market Estimates & Forecast, 2020 – 2027

9.3.3 Craniotomy

9.3.3.1 Market Estimates & Forecast, 2020 – 2027

9.3.4 Microsurgery Removal

9.3.4.1 Market Estimates & Forecast, 2020 – 2027

9.4 Radiation Therapy

9.4.1 Market Estimates & Forecast, 2020 – 2027

9.4.2 Stereotactic Radiotherapy

9.4.2.1 Market Estimates & Forecast, 2020 – 2027

9.4.3 Proton Beam Therapy

9.4.3.1 Market Estimates & Forecast, 2020 – 2027

9.5 Supportive Therapy

9.5.1 Market Estimates & Forecast, 2020 – 2027

9.6 Others

Chapter 10. Global Acoustic Neuroma Market, By End User

10.1 Introduction

10.2 Hospitals

10.2.1 Market Estimates & Forecast, 2020 – 2027

10.3 Diagnostic Centers

10.3.1 Market Estimates & Forecast, 2020 – 2027

10.4 Academic Institutes

10.4.1 Market Estimates & Forecast, 2020 – 2027

10.4 Others

Chapter. 11 Global Acoustic Neuroma Market, By Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.1 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest Of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic Of Korea

11.4.6 Rest Of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest Of The Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 GE Healthcare

13.1.1 Company Overview

13.1.2 Drug Class Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 Siemens Healthcare

13.2.1 Company Overview

13.2.2 Drug Class Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Philips Healthcare

13.3.1 Company Overview

13.3.2 Drug Class Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Shimadzu Corporation

13.4.1 Company Overview

13.4.2 Drug Class/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Toshiba Medical Systems Corporation

13.5.1 Company Overview

13.5.2 Drug Class Overview

13.5.3 Financial Overview

13.5.4 Key Developments

13.6 Novartis AG

13.6.1 Company Overview

13.6.2 Drug Class Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 Merck & Co., Inc.

13.7.1 Overview

13.7.2 Drug Class Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 F. Hoffmann-La Roche Ltd

13.8.1 Company Overview

13.8.2 Drug Class/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Pfizer Inc.

13.9.1 Company Overview

13.9.2 Drug Class Overview

13.9.3 Financial Overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs Of The Market

14.2 Key Companies To Watch

14.3 Prediction Of Pharmaceutical Industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Acoustic Neuroma Industry Synopsis, 2020 – 2027

Table 2 Acoustic Neuroma Market Estimates And Forecast, 2020 – 2027, (USD Million)

Table 3 Acoustic Neuroma Market By Region, 2020 – 2027, (USD Million)

Table 4 Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 5 Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 6 Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 7 Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 8 Acoustic Neuroma Market By End Users, 2020 – 2027, (USD Million)

Table 9 North America Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 10 North America Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 11 North America Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 12 North America Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 13 North America Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 14 US Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 15 US Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 16 US Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 17 US Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 18 US Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 19 Canada Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 20 Canada Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 21 Canada Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 22 Canada Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 23 Canada Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 24 South America Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 25 South America Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 26 South America Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 27 South America Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 28 South America Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 29 Europe Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 30 Europe Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 31 Europe Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 32 Europe Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 33 Europe Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 34 Western Europe Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 35 Western Europe Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 36 Western Europe Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 37 Western Europe Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 38 Western Europe Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 39 Eastern Europe Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 40 Eastern Europe Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 41 Eastern Europe Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 42 Eastern Europe Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 43 Eastern Europe Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 44 Asia Pacific Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 45 Asia Pacific Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 46 Asia Pacific Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 47 Asia Pacific Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 48 Asia Pacific Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

Table 49 The Middle East & Africa Acoustic Neuroma Market By Type, 2020 – 2027, (USD Million)

Table 50 The Middle East & Africa Acoustic Neuroma Market By Diagnosis, 2020 – 2027, (USD Million)

Table 51 The Middle East & Africa Acoustic Neuroma Market By Drug Class, 2020 – 2027, (USD Million)

Table 52 The Middle East & Africa Acoustic Neuroma Market By Treatment, 2020 – 2027, (USD Million)

Table 53 The Middle East & Africa Acoustic Neuroma Market By End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation For Acoustic Neuroma Market

Figure 3 Segmentation Market Dynamics For Acoustic Neuroma Market

Figure 4 Global Acoustic Neuroma Market Share, By Type 2020

Figure 5 Global Acoustic Neuroma Market Share, By Diagnosis, 2020

Figure 6 Global Acoustic Neuroma Market Share, By Drug Class, 2020

Figure 8 Global Acoustic Neuroma Market Share, By Treatment, 2020

Figure 9 Global Acoustic Neuroma Market Share, By End Users, 2020

Figure 10 Global Acoustic Neuroma Market Share, By Region, 2020

Figure 11 North America Acoustic Neuroma Market Share, By Country, 2020

Figure 12 Europe Acoustic Neuroma Market Share, By Country, 2020

Figure 13 Asia Pacific Acoustic Neuroma Market Share, By Country, 2020

Figure 14 The Middle East & Africa Acoustic Neuroma Market Share, By Country, 2020

Figure 15 Global Acoustic Neuroma Market: Company Share Analysis, 2020 (%)

Figure 16 GE Healthcare: Key Financials

Figure 17 GE Healthcare: Segmental Revenue

Figure 18 GE Healthcare: Geographical Revenue

Figure 19 Siemens Healthcare: Key Financials

Figure 20 Siemens Healthcare: Segmental Revenue

Figure 21 Siemens Healthcare: Geographical Revenue

Figure 22 Philips Healthcare: Key Financials

Figure 23 Philips Healthcare: Segmental Revenue

Figure 24 Philips Healthcare: Geographical Revenue

Figure 25 Shimadzu Corporation: Key Financials

Figure 26 Shimadzu Corporation: Segmental Revenue

Figure 27 Shimadzu Corporation: Geographical Revenue

Figure 28 Toshiba Medical Systems Corporation: Key Financials

Figure 29 Toshiba Medical Systems Corporation: Segmental Revenue

Figure 30 Toshiba Medical Systems Corporation: Geographical Revenue

Figure 32 Novartis AG: Key Financials

Figure 33 Novartis AG: Segmental Revenue

Figure 34 Novartis AG: Geographical Revenue

Figure 35 Merck & Co., Inc.: Key Financials

Figure 36 Merck & Co., Inc: Segmental Revenue

Figure 37 Merck & Co., Inc.: Geographical Revenue

Figure 38 F. Hoffmann-La Roche Ltd: Key Financials

Figure 39 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 40 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 41 Pfizer Inc.: Key Financials

Figure 42 Pfizer Inc.: Segmental Revenue

Figure 43 Pfizer Inc.: Geographical Revenue